We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dutch Medical Centre Achieves Accreditation for Clinical use of Microarrays

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

The Dutch Council for Accreditation (RvA) has accredited the Array facility of the Genome Diagnostic section of the University Medical Centre Utrecht with NEN-EN-ISO 15189. This is the first such accreditation, and is of particular importance to the cytogenetics community, as it is the first to include the clinical use of microarrays for arrayCGH.

ArrayCGH uses microarrays to measure genomic copy number imbalance. Until recently it was reserved for those patients left undiagnosed by traditional approaches such as karyotyping and fluorescent in-situ hybridization (FISH).

Increasingly however arrayCGH is used, in combination with karyotyping, as a primary screen in order to deliver high resolution genetic information around which further investigations may be planned.

The quality system for genetic diagnostics at the University Medical Centre has been developed to meet NEN-EN-ISO 15189, the ISO standard for quality and competence in medical laboratories. The accreditation with the RvA describes the methods, equipment and reporting required for clinical arrayCGH.

In order to achieve the accreditation the BlueGnome CytoChip™ was selected to replace the academic microarray used to establish the service.

Marcel Nelen, Clinical Molecular Geneticist responsible explained, “Comparing the first 300 patients investigated using the CytoChip™ with the last 300 processed using our academic microarray we have increased our diagnostic yield while reducing false positives and failed investigations. This translates into a service for our patients that is faster, more cost effective and more clinically informative”.

Dr Nick Haan, CEO of BlueGnome confirmed, “Clinical applications demand levels of quality and repeatability which are difficult to obtain with a research platform. A more rigorous regulatory framework for clinical applications is to be expected and is something that we plan to support with the CE marking of the CytoChip as an in vitro medical device”.